Literature DB >> 10762127

The spectrum of levodopa-induced dyskinesias.

S Fahn1.   

Abstract

The most common types of levodopa-induced dyskinesias in patients with Parkinson's disease (PD) are chorea and dystonia, and often the two types are intermixed. Myoclonus is a far less common problem. The dyskinesias tend to develop over time, not usually being encountered at the initiation of levodopa therapy. Eventually, they affect more than 50% of patients on long-term levodopa treatment. Once they appear, they are difficult to eliminate. Substituting weaker dopaminergic agents for levodopa often fails to eliminate the dyskinesias. Most of the dyskinesias occur at the time of the highest brain concentration of levodopa and its product, dopamine--so-called peak-dose dyskinesias. Chorea and dystonia, usually in the legs, occur less commonly at the beginning and end of dosing, and these are called diphasic dyskinesias. Dystonia can also occur during the 'off' state, i.e. when the levodopa concentration is low. These 'off' dystonias are often painful and must be distinguished from peak-dose dystonia and from dystonia that may be a feature of PD itself.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10762127

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  59 in total

Review 1.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  The influence of levodopa-induced dyskinesias on manual tracking in patients with Parkinson's disease.

Authors:  Sarah Lemieux; Mehrdad Ghassemi; Mandar Jog; Roderick Edwards; Christian Duval
Journal:  Exp Brain Res       Date:  2006-08-30       Impact factor: 1.972

3.  The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors.

Authors:  K E Soderstrom; G Meredith; T B Freeman; S O McGuire; T J Collier; C E Sortwell; Qun Wu; K Steece-Collier
Journal:  Neurobiol Dis       Date:  2008-07-11       Impact factor: 5.996

4.  Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats.

Authors:  Anna Jiménez; Merce Bonastre; Esther Aguilar; Concepcio Marin
Journal:  Psychopharmacology (Berl)       Date:  2009-07-28       Impact factor: 4.530

Review 5.  Presynaptic effects of levodopa and their possible role in dyskinesia.

Authors:  Eugene V Mosharov; Anders Borgkvist; David Sulzer
Journal:  Mov Disord       Date:  2014-12-01       Impact factor: 10.338

6.  Abnormal Cortico-Basal Ganglia Neurotransmission in a Mouse Model of l-DOPA-Induced Dyskinesia.

Authors:  Indriani Dwi Wahyu; Satomi Chiken; Taku Hasegawa; Hiromi Sano; Atsushi Nambu
Journal:  J Neurosci       Date:  2021-02-09       Impact factor: 6.167

Review 7.  Pathological basal ganglia activity in movement disorders.

Authors:  T Wichmann; J O Dostrovsky
Journal:  Neuroscience       Date:  2011-06-22       Impact factor: 3.590

8.  Homocysteine and A2A-D2 Receptor-Receptor Interaction at Striatal Astrocyte Processes.

Authors:  Chiara Cervetto; Arianna Venturini; Diego Guidolin; Guido Maura; Mario Passalacqua; Carlo Tacchetti; Pietro Cortelli; Susanna Genedani; Simona Candiani; Paola Ramoino; Simone Pelassa; Manuela Marcoli; Luigi F Agnati
Journal:  J Mol Neurosci       Date:  2018-07-20       Impact factor: 3.444

Review 9.  Potential of transdermal drug delivery in Parkinson's disease.

Authors:  Ronald F Pfeiffer
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

10.  Assessment of Treatment Patterns and Patient Outcomes in Levodopa-Induced Dyskinesias (ASTROID): A US Chart Review Study.

Authors:  Barb Lennert; Wendy Bibeau; Eileen Farrelly; Patricia Sacco; Tessa Schoor
Journal:  Am Health Drug Benefits       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.